Related Experiment Videos
Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.
Anticancer Research
|May 1, 1987
Summary
In multiple myeloma (MM), 9% of patients maintained normal serum beta-2-microglobulin (B2M) levels, indicating some tumors may not produce or secrete B2M. This finding may impact B2M
Area of Science:
- Oncology
- Clinical Chemistry
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Serum beta-2-microglobulin (B2M) is a common prognostic marker in MM.
Purpose of the Study:
- To investigate the behavior of serum B2M levels in a cohort of multiple myeloma patients.
- To assess the utility of B2M as a clinical marker in MM.
Main Methods:
- Serum B2M levels were measured in 90 patients with MM.
- Patients were monitored from diagnosis through to death or terminal disease phase.
Main Results:
- 9% of patients (8 out of 90) exhibited normal serum B2M levels throughout their follow-up.
- This subset included IgA MM, light chain MM, and non-secretory MM cases.
- These findings suggest potential heterogeneity in B2M production/secretion among MM tumors.
Conclusions:
- A subset of multiple myeloma patients may not produce or secrete detectable levels of B2M.
- The clinical utility of serum B2M as a universal marker in MM may be limited in certain cases.